drugset / Trial / NCT00887926
Study of IMC-EB10 in Participant With Leukemia
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if IMC-EB10 is safe for participants with leukemia, and also to determine the best dose of IMC-EB10 to give to participants.
Timeline
- Start
- 2009-06
- Primary completion
- 2010-08
- Completion
- 2010-08
Outcome
Outcome not reported
Stopped: “Lack of efficacy”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMC-EB10 | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | IMC-EB10 | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | IMC-EB10 | Monoclonal antibody | 20 mg/kg | Intravenous |
| Subject | IMC-EB10 | Monoclonal antibody | 30 mg/kg | Intravenous |